AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totalling 6,217,224 shares, a decline of 16.6% from the August 15th total of 7,453,039 shares. Currently, 18.5% of the company’s shares are short sold. Based on an average trading volume of 711,900 shares, the short-interest ratio is currently 8.7 days.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 24.16 on Friday. AMAG Pharmaceuticals has a 52-week low of $17.92 and a 52-week high of $49.62. The firm’s market cap is $825.16 million. The company has a 50 day moving average price of $24.56 and a 200-day moving average price of $23.79.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.20 by $0.25. AMAG Pharmaceuticals had a positive return on equity of 13.98% and a negative net margin of 4.87%. The firm earned $127.40 million during the quarter, compared to the consensus estimate of $128.52 million. During the same period last year, the business posted $1.12 EPS. The business’s revenue was up 46.7% compared to the same quarter last year. On average, analysts expect that AMAG Pharmaceuticals will post $5.43 earnings per share for the current fiscal year.
AMAG has been the topic of several recent analyst reports. Jefferies Group reduced their target price on AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating on the stock in a report on Wednesday, August 10th. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Friday, August 12th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $36.78.
A number of hedge funds have recently modified their holdings of AMAG. BlackRock Inc. increased its stake in shares of AMAG Pharmaceuticals by 528.5% in the first quarter. BlackRock Inc. now owns 4,299 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 3,615 shares during the last quarter. Teacher Retirement System of Texas increased its stake in shares of AMAG Pharmaceuticals by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 4,864 shares of the specialty pharmaceutical company’s stock worth $116,000 after buying an additional 589 shares during the last quarter. Mason Street Advisors LLC acquired a new stake in shares of AMAG Pharmaceuticals during the second quarter worth $162,000. Legal & General Group Plc increased its stake in shares of AMAG Pharmaceuticals by 43.3% in the first quarter. Legal & General Group Plc now owns 9,492 shares of the specialty pharmaceutical company’s stock worth $221,000 after buying an additional 2,870 shares during the last quarter. Finally, Societe Generale acquired a new stake in shares of AMAG Pharmaceuticals during the second quarter worth $232,000.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.